257 related articles for article (PubMed ID: 34535173)
1. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway.
Hu W; Li M; Chen Y; Gu X
J Ovarian Res; 2021 Sep; 14(1):121. PubMed ID: 34535173
[TBL] [Abstract][Full Text] [Related]
2. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
3. Ube2S regulates Wnt/β-catenin signaling and promotes the progression of non-small cell lung cancer.
Qin Y; Du J; Fan C
Int J Med Sci; 2020; 17(2):274-279. PubMed ID: 32038111
[TBL] [Abstract][Full Text] [Related]
4. N
Fukumoto T; Zhu H; Nacarelli T; Karakashev S; Fatkhutdinov N; Wu S; Liu P; Kossenkov AV; Showe LC; Jean S; Zhang L; Zhang R
Cancer Res; 2019 Jun; 79(11):2812-2820. PubMed ID: 30967398
[TBL] [Abstract][Full Text] [Related]
5. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
6. PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/
Zhang X; Sun M; Jiao Y; Lin B; Yang Q
Oxid Med Cell Longev; 2022; 2022():9029544. PubMed ID: 36105480
[TBL] [Abstract][Full Text] [Related]
7. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
9. UBE2S mediates tumor progression via SOX6/β-Catenin signaling in endometrial cancer.
Lin M; Lei T; Zheng J; Chen S; Du L; Xie H
Int J Biochem Cell Biol; 2019 Apr; 109():17-22. PubMed ID: 30690078
[TBL] [Abstract][Full Text] [Related]
10. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.
Wang Z; Gao J; Zhou J; Liu H; Xu C
J Gynecol Oncol; 2019 Mar; 30(2):e26. PubMed ID: 30740957
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
13. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
14. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
15. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E; Gerini G; Megiorni F; Anastasiadou E; Pontecorvi P; Solito L; De Vitis C; Camero S; Marchetti C; Mancini R; Benedetti Panici P; Dominici C; Romano F; Angeloni A; Marchese C; Ceccarelli S
J Exp Clin Cancer Res; 2020 Jan; 39(1):3. PubMed ID: 31898520
[TBL] [Abstract][Full Text] [Related]
16. LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells.
Xiang J; Zhou L; He Y; Wu S
Aging (Albany NY); 2021 Dec; 13(24):25920-25930. PubMed ID: 34919531
[TBL] [Abstract][Full Text] [Related]
17. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
Chen Y; Du H
Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
[TBL] [Abstract][Full Text] [Related]
18. Ube2s stabilizes β-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development.
Li Z; Wang Y; Li Y; Yin W; Mo L; Qian X; Zhang Y; Wang G; Bu F; Zhang Z; Ren X; Zhu B; Niu C; Xiao W; Zhang W
Cell Death Dis; 2018 May; 9(5):456. PubMed ID: 29674637
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
20. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]